Black Diamond Therapeutics Inc

NASDAQ:BDTX  
34.43
+1.00 (+2.99%)
Other Pre-Announcement

Black Diamond Therapeutics Reports Q3 Loss Per Share Of $0.50

Published: 11/10/2020 13:02 GMT
(BDTX) - Black Diamond Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update.
Black Diamond Therapeutics - Cash, Cash Equivalents, Investments of $333.1 Million As of Sept 30, Expected to Be Sufficient to Fund Operations Into 2023.
Qtrly Loss per Share $0.50.
Q3 Earnings per Share View $-0.52 -- Refinitiv Ibes Data (analyst estimates).